LogicBio Therapeutics, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
65 Hayden Ave, 2 Nd Floor, Lexington, MA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2022 - Nov 14, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 247 % -61.8%
Debt-to-equity 117 % +131%
Return On Equity -115 % -51.7%
Return On Assets -53 % -5.22%
Operating Margin -241 % +74.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33M shares +0.02%
Common Stock, Shares, Outstanding 33M shares +0.05%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 33M shares +1.6%
Weighted Average Number of Shares Outstanding, Diluted 33M shares +1.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 10.8M USD +174%
Research and Development Expense 22.2M USD -13.5%
General and Administrative Expense 14.4M USD -2.92%
Operating Income (Loss) -25.9M USD +29.3%
Nonoperating Income (Expense) -654K USD +39.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -5.78M USD +43.5%
Net Income (Loss) Attributable to Parent -26.5M USD +29.9%
Earnings Per Share, Basic -0.18 USD/shares +41.9%
Earnings Per Share, Diluted -0.18 USD/shares +41.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 30.8M USD -48.3%
Assets, Current 32.8M USD -46%
Property, Plant and Equipment, Net 1.5M USD -25.9%
Operating Lease, Right-of-Use Asset 3.7M USD -23.7%
Assets 38.6M USD -43.4%
Accounts Payable, Current 1.11M USD +23%
Employee-related Liabilities, Current 1.65M USD -10.8%
Accrued Liabilities, Current 2.32M USD -33%
Liabilities, Current 16.4M USD +20%
Operating Lease, Liability, Noncurrent 2.71M USD -33%
Liabilities 22.9M USD -22.3%
Retained Earnings (Accumulated Deficit) -158M USD -20.3%
Stockholders' Equity Attributable to Parent 15.7M USD -59.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 15.7M USD -59.4%
Liabilities and Equity 38.6M USD -43.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.9M USD -22.6%
Net Cash Provided by (Used in) Financing Activities -833K USD -140%
Net Cash Provided by (Used in) Investing Activities -7K USD +95.4%
Common Stock, Shares Authorized 175M shares 0%
Common Stock, Shares, Issued 33M shares +0.05%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.7M USD -75.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31.4M USD -47.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 170K USD -22%
Operating Lease, Liability 4.05M USD -22.8%
Payments to Acquire Property, Plant, and Equipment 7K USD -95.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -26.5M USD +29.9%
Lessee, Operating Lease, Liability, to be Paid 4.5M USD -25.6%
Operating Lease, Liability, Current 1.34M USD +11.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 456K USD -44%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Operating Lease, Payments 385K USD +3.22%
Additional Paid in Capital 173M USD +2.07%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 837K USD -24%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%